346 related articles for article (PubMed ID: 18086519)
1. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.
Mittmann N; Kuramoto L; Seung SJ; Haddon JM; Bradley-Kennedy C; Fitzgerald JM
Respir Med; 2008 Mar; 102(3):413-21. PubMed ID: 18086519
[TBL] [Abstract][Full Text] [Related]
2. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
Jahnz-Rózyk K; Targowski T; From S
Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
[TBL] [Abstract][Full Text] [Related]
3. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.
Chiang CH
Respirology; 2008 Sep; 13(5):689-94. PubMed ID: 18513247
[TBL] [Abstract][Full Text] [Related]
4. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of outpatient and inpatient costs of moderate and severe exacerbations of chronic obstructive pulmonary disease in Poland].
Jahnz-Rózyk K; Targowski T; From S
Pneumonol Alergol Pol; 2008; 76(6):426-31. PubMed ID: 19173191
[TBL] [Abstract][Full Text] [Related]
6. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
7. Economic burden prior to COPD diagnosis: a matched case-control study in the United States.
Akazawa M; Halpern R; Riedel AA; Stanford RH; Dalal A; Blanchette CM
Respir Med; 2008 Dec; 102(12):1744-52. PubMed ID: 18760581
[TBL] [Abstract][Full Text] [Related]
8. [Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].
Jahnz-Różyk K; Targowski T; From S; Faluta T; Borowiec L
Pneumonol Alergol Pol; 2011; 79(5):337-42. PubMed ID: 21861257
[TBL] [Abstract][Full Text] [Related]
9. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.
Toy EL; Gallagher KF; Stanley EL; Swensen AR; Duh MS
COPD; 2010 Jun; 7(3):214-28. PubMed ID: 20486821
[TBL] [Abstract][Full Text] [Related]
10. Treatment cost of acute exacerbations of chronic bronchitis.
Niederman MS; McCombs JS; Unger AN; Kumar A; Popovian R
Clin Ther; 1999 Mar; 21(3):576-91. PubMed ID: 10321424
[TBL] [Abstract][Full Text] [Related]
11. Healthcare costs of COPD in Italian referral centres: a prospective study.
Koleva D; Motterlini N; Banfi P; Garattini L;
Respir Med; 2007 Nov; 101(11):2312-20. PubMed ID: 17681461
[TBL] [Abstract][Full Text] [Related]
12. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.
Yu AP; Yang H; Wu EQ; Setyawan J; Mocarski M; Blum S
J Med Econ; 2011; 14(3):315-23. PubMed ID: 21500975
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of chronic obstructive pulmonary disease.
Teo WS; Tan WS; Chong WF; Abisheganaden J; Lew YJ; Lim TK; Heng BH
Respirology; 2012 Jan; 17(1):120-6. PubMed ID: 21954985
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease.
Dalal AA; Shah M; Lunacsek O; Hanania NA
Respir Med; 2011 Oct; 105(10):1516-22. PubMed ID: 21684731
[TBL] [Abstract][Full Text] [Related]
15. Predictors of hospital admission for chronic obstructive pulmonary disease exacerbations in Canadian emergency departments.
Rowe BH; Villa-Roel C; Guttman A; Ross S; Mackey D; Sivilotti ML; Worster A; Stiell IG; Willis V; Borgundvaag B
Acad Emerg Med; 2009 Apr; 16(4):316-24. PubMed ID: 19298621
[TBL] [Abstract][Full Text] [Related]
16. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.
Menzin J; Boulanger L; Marton J; Guadagno L; Dastani H; Dirani R; Phillips A; Shah H
Respir Med; 2008 Sep; 102(9):1248-56. PubMed ID: 18620852
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic analysis of antimicrobial therapy of chronic obstructive pulmonary disease exacerbations.
Simoens S; Decramer M; De Coster S; Celis G; Laekeman G
Int J Clin Pract; 2007 Feb; 61(2):200-6. PubMed ID: 17263707
[TBL] [Abstract][Full Text] [Related]
18. Economic aspects of antimicrobial therapy of acute exacerbations of COPD.
Simoens S; Decramer M; Laekeman G
Respir Med; 2007 Jan; 101(1):15-26. PubMed ID: 16650975
[TBL] [Abstract][Full Text] [Related]
19. Retrospective incremental cost analysis of a hospital-based COPD Disease Management Programme in Sweden.
Tunsäter A; Moutakis M; Borg S; Persson U; Strömberg L; Nielsen AL
Health Policy; 2007 May; 81(2-3):309-19. PubMed ID: 16904788
[TBL] [Abstract][Full Text] [Related]
20. Direct medical costs of COPD--an excess cost approach based on two population-based studies.
Menn P; Heinrich J; Huber RM; Jörres RA; John J; Karrasch S; Peters A; Schulz H; Holle R;
Respir Med; 2012 Apr; 106(4):540-8. PubMed ID: 22100535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
